Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: Pathogenesis and therapeutic options

Published 2016 View Full Article

Authors

Keywords

renal cell carcinoma, rapalog therapy, immunohistochemistry, MTORC2, resistance

Journal

Oncotarget

Volume 7, Issue 27, Pages -

Publisher

Impact Journals, LLC

Online

2016-05-22

DOI

10.18632/oncotarget.9508

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started